The progression of cancer involves a critical step in which malignant cells escape from
control by the immune system. Antineoplastic agents are particularly efficient when they …

The current standard-of-care adjuvant treatment for patients with colorectal cancer (CRC)
comprises a fluoropyrimidine (5-fluorouracil or capecitabine) as a single agent or in …

Background Mismatch repair–deficient (dMMR) tumors can be found in 10 to 15% of patients
with nonmetastatic colon cancer. In these patients, the efficacy of chemotherapy is limited …

Bioengineered probiotics enable new opportunities to improve colorectal cancer (CRC)
screening, prevention and treatment. Here, first, we demonstrate selective colonization of …

Glioblastoma is a clinically and molecularly heterogeneous disease, and new predictive
biomarkers are needed to identify those patients most likely to respond to specific …

CAMILLA is a basket trial (NCT03539822) evaluating cabozantinib plus the ICI durvalumab
in chemorefractory gastrointestinal cancer. Herein, are the phase II colorectal cohort results …

Background The immune response has important clinical value in colorectal cancer (CRC)
in both prognosis and response to immunotherapy. This study aims to explore tumour …

In the Modern era, immune checkpoint inhibitors (ICIs) have been the cornerstone of
success in the treatment of several malignancies. Despite remarkable therapeutic advances …

PD-1 blockade unleashes potent antitumor activity in CD8+ T cells but can also promote
immunosuppressive T regulatory (Treg) cells, which may worsen the response to …

WRN helicase is a promising target for treatment of cancers with microsatellite instability
(MSI) due to its essential role in resolving deleterious non-canonical DNA structures that …